Ganli Pharmaceutical declares ultra-long-acting insulin once a week

On November 30, Ganli Pharmaceutical announced that its weekly ultra-long-acting insulin weekly preparation GZR4 clinical trial application has been accepted by NMPA (acceptance number: CXSL2101457, the official website has not yet been published)

Prior to this, on October 25, the glucagon-like peptide 1 (GLP-1) receptor agonist GZR18, which was injected once a week by Ganli Pharmaceutical, had just been approved for clinical use for type II diabetes, obesity and overweight

According to the latest data released by the International Diabetes Federation (IDF) Global Diabetes Overview 9th Edition (2019), there are currently 463 million adults (20-79 years old) living with diabetes worldwide

Among the insulin drugs currently on the market, insulin analogues occupy a major share of the insulin market due to their relatively good safety and lower immunogenicity

Insulin centralized procurement group 5 winning bids

From: Shanghai Sunshine Purchasing Network, compiled by Insight

However, the half-lives of long-acting basal insulin analogues currently on the market are about 10~26 hours, and the duration of action is only about one day

Up to now, no weekly insulin preparation products have been approved for the market worldwide.

Icodec project details

From Insight database (http://db.

As of September 30, 2021, Ganli Pharmaceutical has invested a total of RMB 30.